(N = 14) | |
---|---|
Patient characteristics | |
Age, mean ± SD, years | 49.3 ± 8.66 |
Male sex, n (%) | 14 (100) |
Race, n (%) | |
White | 12 (85.7) |
Asian | 2 (14.3) |
Body mass index (BMI), mean ± SD, kg/m2 | 33.9 ± 6.96 |
Smoking status, n (%) | |
Never | 4 (28.6) |
Current | 5 (35.7) |
Former | 5 (35.7) |
Comorbidities, n (%) | |
Vascular disorders | 7 (50.0) |
Hypertension | 5 (35.7) |
Deep vein thrombosis | 1 (7.1) |
Peripheral venous disease | 1 (7.1) |
Thrombosis | 1 (7.1) |
Varicose vein | 1 (7.1) |
Respiratory, thoracic, and mediastinal disordersa | 6 (42.9) |
Gastrointestinal disordersb | 5 (35.7) |
Nervous system disordersc | 4 (28.6) |
Psychiatric disordersd | 4 (28.6) |
Elevated alanine aminotransferase | 3 (21.4) |
Obesity | 3 (21.4) |
General disorders and administration site conditionse | 3 (21.4) |
Hepatobiliary disordersf | 2 (14.3) |
Nephrolithiasis | 2 (14.3) |
Erectile dysfunction | 1 (7.1) |
Atrial fibrillation | 1 (7.1) |
Gout characteristics and assessments | |
Prior occurrence of tophi, n (%) | 13 (92.9) |
Time since first gout diagnosis, mean ± SD, years | 13.8 ± 7.44 |
Serum uric acid, mean ± SD, mg/dL | 9.2 ± 2.49 |
Prior oral urate-lowering therapy use | 12 (85.7) |
Allopurinol | 11 (78.6) |
Febuxostat | 3 (21.4) |
Probenecid | 0 |